Associated Genetic Biomarkers
ARID1B Mutation is present in 3.93% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence .
ARID1B Mutation serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain ARID1B Mutation as an inclusion criterion, 2 are phase 2 (2 open).
Trials with ARID1B Mutation in the inclusion eligibility criteria most commonly target melanoma .
Niraparib, olaparib, and pembrolizumab are the most frequent therapies in trials with ARID1B Mutation as an inclusion criteria .
Significance of ARID1B Mutation in Diseases
ARID1B is altered in 9.26% of melanoma patients with ARID1B Mutation present in 8.09% of all melanoma patients .
ARID1B Mutation is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1B Mutation and melanoma as inclusion criteria, 2 are phase 2 (2 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.